Compare WNC & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WNC | SLN |
|---|---|---|
| Founded | 1985 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 88 |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 325.8M | 300.9M |
| IPO Year | 2009 | N/A |
| Metric | WNC | SLN |
|---|---|---|
| Price | $12.89 | $9.21 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $11.00 | ★ $42.60 |
| AVG Volume (30 Days) | ★ 976.1K | 648.2K |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.84% | N/A |
| EPS Growth | ★ 179.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,027,489,000.00 | N/A |
| Revenue This Year | $10.65 | N/A |
| Revenue Next Year | $14.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.81 | N/A |
| 52 Week Low | $6.63 | $4.19 |
| 52 Week High | $14.32 | $11.06 |
| Indicator | WNC | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 65.69 | 55.24 |
| Support Level | $8.34 | $5.87 |
| Resistance Level | $12.94 | $11.06 |
| Average True Range (ATR) | 0.71 | 0.90 |
| MACD | -0.16 | -0.03 |
| Stochastic Oscillator | 50.68 | 55.45 |
Wabash National Corp operates as the innovation leader of connected solutions for the transportation, logistics, and distribution industries. The Company manages its business in two operating and reportable segments: Transportation Solutions and Parts & Services. It designs and manufactures products including dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food-grade processing equipment.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.